Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...

GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson’s Disease

Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's ...

GEN Ilac ve Saglik Urunleri A.S.: GEN Announces First Patient Dosed in Phase II Clinical Trial of SUL-238 in Parkinson's Disease

Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease. ANKARA, TR / ACCESS Newswire / June 8, 2026 / GEN Pharmaceuticals (GENIL.I ...
list25 on MSN

25 disturbing things your brain does while you sleep

Discover the 25 disturbing things your brain does while you sleep. From processing trauma to deleting memories and simulating ...

Why Consumer AI Agents Need Runtime Security, Not Just Governance

Without the right controls, consumer-facing AI agents can expose organizations to regulatory violations, privacy breaches, ...